Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, has been named one of the Top Places to Work in Massachusetts in the 12th annual employee-based survey project from The Boston Globe. Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best—their employees.
Beam was ranked as the top biotechnology company in the small employers category. Based in Cambridge, Beam currently has more than 110 employees in the Massachusetts area.
“It is such an honor for the Beam team to be recognized by the Boston Globe’s Top Places to Work list,” said John Evans, chief executive officer of Beam Therapeutics. “From the beginning we have set out to build a strong, values-driven organization that is focused on the success of our people, while advancing cutting-edge science and developing a new class of precision genetic medicines.”
The rankings in Top Places to Work are based on confidential survey information collected by Energage (formerly WorkplaceDynamics), an independent company specializing in employee engagement and retention, from nearly 66,000 individuals at 323 Massachusetts organizations. The winners share a few key traits, including offering progressive benefits, giving their employees a voice, and encouraging them to have some fun while they’re at it.
About Beam Therapeutics
Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Beam is headquartered in Cambridge, Massachusetts. For additional information, visit www.BeamTx.com.
About Boston Globe Media Partners LLC
Boston Globe Media Partners, LLC provides news and information, entertainment, opinion and analysis through its multimedia properties. BGMP includes The Boston Globe, Globe.com, Boston.com, STAT and Globe Direct.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191115005215/en/
Source: Beam Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20191115005215/en
